

ABN: 80 063 114 045 Level 1, 39 Leveson Street North Melbourne, Vic 3051 Tel: +61 3 8637 1107 Fax: +61 3 9328 1675

Fax: +61 3 9328 1675 www.immuron.com

## IMMURON COLLABORATES WITH SYNLAIT FOR PRODUCTION OF HYPERIMMUNE COLOSTRUM

- Immuron prepares for expected volume ramp up
- Synlait specialises in high quality value added dairy products
- Synlait has the capacity to meet Immuron's increasing requirements

**Melbourne, Australia, 7 May 2012**: Australian biopharmaceutical company Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into an agreement with Synlait Milk Ltd for the production of Immuron's hyperimmune colostrum in anticipation of Immuron's need for increased supply capacity.

Synlait is an innovative dairy processing company based in Canterbury, New Zealand. It specialises in producing infant and adult nutritional formulations, functional food ingredients, and specialised products to support a healthy lifestyle. Synlait's production systems feature the latest technology and have fully integrated and controlled systems. For instance, Synlait controls tight calving patterns and has its own in-house veterinary capabilities which results in Synlait being able to deliver significant efficiencies with economies of scale.

Immuron's Chief Executive Officer Joe Baini said: "As Immuron embarks on an era of increased global distribution of Travelan and other products, it is imperative to have a partner able to accommodate the anticipated significant increase in supply capacity. Synlait, with its impressive infrastructure and expertise is an ideal partner."

Synlait's General Manager Nutritionals, Dr Tony McKenna said: "We are excited to partner with Immuron and be part of its growth journey. Our partnership with Immuron adds another value-added dairy product to our suite of such products, for which we believe global demand will continue to grow."

## **Contact**

Joe Baini – Chief Executive Officer +61 3 8637 1107 Rudi Michelson Monsoon Communications +61 3 9620 3333 +61 411 402 737

## **About Immuron Limited**

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron's products will be expedited. Immuron's current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers' diarrhoea. Immuron's main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).

## **About Synlait**

Synlait is an innovative dairy processing company based in the heart of Canterbury, New Zealand. It combines expert farming, with state-of-the-art processing, to produce a range of nutritional milk products that provide genuine benefits for health and wellbeing. They include infant and adult nutritional formulations, functional food ingredients, and specialised products to support a healthy lifestyle. Synlait controls the quality of milk supply, milk processing and market distribution to guarantee absolute food safety, security and traceability.